Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702772 | 0.93 | — | — | |
| SCHEMBL1702289 | 0.85 | — | — | |
| SCHEMBL1702712 | 0.82 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL2451054 | 0.82 | ROCK2 (0.35) | CYP3A4 | |
| SCHEMBL1702297 | 0.82 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL1703325 | 0.81 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL2452150 | 0.80 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL2452144 | 0.80 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL1702714 | 0.79 | — | — | |
| SCHEMBL16152430 | 0.78 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | claimed |
| EP-2440528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | claimed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | claimed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | TNF 3958/4885CYP3A4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.